Caribou Biosciences Inc (NASDAQ: CRBU)’s stock price has gone rise by 10.34 in comparison to its previous close of 1.16, however, the company has experienced a 8.47% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-28 that BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT.
Is It Worth Investing in Caribou Biosciences Inc (NASDAQ: CRBU) Right Now?
Company’s 36-month beta value is 2.44.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CRBU is 80.97M, and currently, short sellers hold a 10.30% ratio of that floaft. The average trading volume of CRBU on June 20, 2025 was 1.10M shares.
CRBU’s Market Performance
CRBU stock saw an increase of 8.47% in the past week, with a monthly gain of 21.90% and a quarterly increase of 34.61%. The volatility ratio for the week is 5.92%, and the volatility levels for the last 30 days are 6.76% for Caribou Biosciences Inc (CRBU). The simple moving average for the last 20 days is 13.45% for CRBU’s stock, with a simple moving average of -14.58% for the last 200 days.
Analysts’ Opinion of CRBU
Many brokerage firms have already submitted their reports for CRBU stocks, with Evercore ISI repeating the rating for CRBU by listing it as a “In-line.” The predicted price for CRBU in the upcoming period, according to Evercore ISI is $3 based on the research report published on June 03, 2024 of the previous year 2024.
Evercore ISI gave a rating of “Outperform” to CRBU, setting the target price at $13 in the report published on October 31st of the previous year.
CRBU Trading at 34.47% from the 50-Day Moving Average
After a stumble in the market that brought CRBU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.33% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBU starting from Haurwitz Rachel E., who purchase 20,000 shares at the price of $1.02 back on Mar 14 ’25. After this action, Haurwitz Rachel E. now owns 3,369,395 shares of Caribou Biosciences Inc, valued at $20,400 using the latest closing price.
MCCLUNG BARBARA G, the Chief Legal Officer of Caribou Biosciences Inc, sale 3,564 shares at $1.35 during a trade that took place back on Feb 21 ’25, which means that MCCLUNG BARBARA G is holding 443,502 shares at $4,811 based on the most recent closing price.
Stock Fundamentals for CRBU
Current profitability levels for the company are sitting at:
- -21.62 for the present operating margin
- 0.73 for the gross margin
The net margin for Caribou Biosciences Inc stands at -19.55. The total capital return value is set at -0.67. Equity return is now at value -52.76, with -43.46 for asset returns.
Based on Caribou Biosciences Inc (CRBU), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -5.25.
Currently, EBITDA for the company is -166.62 million with net debt to EBITDA at 0.02. When we switch over and look at the enterprise to sales, we see a ratio of 15.31. The receivables turnover for the company is 3.92for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.63.
Conclusion
In a nutshell, Caribou Biosciences Inc (CRBU) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
